title: Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases.
abstract: The economic burden of acromegaly in the US has been largely unknown. We describe the prevalence of treatment patterns, complication rates, and associated healthcare utilization and costs of acromegaly in the US. Patients were identified between 1/1/2002 and 12/31/2009 in claims databases. During 1-year after each continuously-enrolled patient's first acromegaly claim, pharmacy and medical claims were used to estimate outcomes. Regression models were used to adjust outcomes. There were 2,171 acromegaly patients (mean age: 45.3 years; 49.7% female); 77.8% received the majority of their care from non-endocrinologists. Pharmacologic treatment was used by 30.8% of patients: octreotide-LAR in 18.6%, dopamine agonists in 9.8%, short-acting octreotide in 4.7%, pegvisomant in 4.1%, and lanreotide in 1.2%; 56% had biochemical monitoring. Comorbidities were common, ranging from 6.6% (colon neoplasms) to 25.6% (musculoskeletal abnormalities). Mean healthcare costs were $24,900. Adjusted analyses indicated comorbidities increased the odds of hospitalization: by 76% for musculoskeletal abnormalities; 193% for cardiovascular abnormalities; and 56% for sleep apnea (p < 0.05). Odds of emergency department visits increased by 87% (musculoskeletal) and 132% (cardiovascular abnormalities) (p < 0.01). After adjustments, colon neoplasms were associated with $8,401 mean increase in costs; musculoskeletal abnormalities with $7,502, cardiovascular abnormalities with $13,331, sleep apnea with $10,453, and hypopituitarism with $6,742 (p < 0.01). Complications are common and increase utilization and cost in acromegaly patients. Cardiovascular complications nearly tripled the odds of hospitalization (OR 2.93) and increased annual mean cost by $13,331. Adequate management of this disease may be able to reduce health care utilization and cost associated with these complications and with acromegaly in general.
authors.affiliation: Partnership for Health Analytic Research, LLC, 280 S. Beverly Dr., Suite 404, Beverly Hills, CA, 90212-3904, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Broder
authors.forename: M P
authors.initials: MP
authors.lastname: Neary
authors.forename: E
authors.initials: E
authors.lastname: Chang
authors.forename: D
authors.initials: D
authors.lastname: Cherepanov
authors.forename: L
authors.initials: L
authors.lastname: Katznelson
mesh_terms: D000172:Acromegaly / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D000293:Adolescent; D000328:Adult; D000368:Aged; D016208:Databases, Factual; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D014481:United States; D055815:Young Adult
references.citation: Pituitary. 2013 Sep;16(3):354-62
references.pmid: 23054327
references.citation: Pituitary. 2011 Sep;14(3):284-94
references.pmid: 21597975
references.citation: J Endocrinol Invest. 2004 Dec;27(11):1034-9
references.pmid: 15754735
references.citation: Health Aff (Millwood). 2001 Nov-Dec;20(6):267-78
references.pmid: 11816667
references.citation: J Chronic Dis. 1987;40(5):373-83
references.pmid: 3558716
references.citation: Am J Med Qual. 2006 Jul-Aug;21(4):269-75
references.pmid: 16849784
references.citation: Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):555-74
references.pmid: 19945023
references.citation: J Clin Epidemiol. 1992 Jun;45(6):613-9
references.pmid: 1607900
references.citation: Endocr Pract. 2011 Jul-Aug;17 Suppl 4:1-44
references.pmid: 21846616
references.citation: Endocr Rev. 2004 Feb;25(1):102-52
references.pmid: 14769829
references.citation: Med Care. 2007 Jun;45(6):562-70
references.pmid: 17515784
references.citation: Clin Invest Med. 2006 Feb;29(1):29-39
references.pmid: 16553361
references.citation: Endocr Pract. 2001 May-Jun;7(3):170-80
references.pmid: 11421563
references.citation: Neuroendocrinology. 2006;83(3-4):139-44
references.pmid: 17047376
references.citation: N Engl J Med. 2006 Dec 14;355(24):2558-73
references.pmid: 17167139
references.citation: J Clin Endocrinol Metab. 2008 Jan;93(1):61-7
references.pmid: 17971431